NCT00407121

WithdrawnPhase 3

Intravitreal Bevacizumab for Inflammatory Neovascular Membra...

Asociación para Evitar la Ceguera en México Source

Asociación para Evitar la Ceguera en México

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

APEC-0025

Study Type

interventional

Actual enrollment (reported)

0

Locations

1 country

Sites

1

Timeline

Study Start

December 2006

Actual (reported)

Primary Completion

December 2006

Actual (reported)

Study Completion

December 2006

Actual (reported)

Brief Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: withdrawn
Actual enrollment (reported): 0 participants
Study completion date: December 2006
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
December 2006
Actual (reported)
Primary Completion
December 2006
Actual (reported)
Study Completion
December 2006
Actual (reported)
First Submitted
December 1, 2006
Actual (reported)
First Posted
December 4, 2006
Actual (reported)

Last Updated: May 30, 2024
Status Verified: May 2024
Last Update Submitted: May 29, 2024

Conditions

Multifocal Choroiditis Serpiginous Choroiditis Vogt Koyanagi Harada Disease

Keywords

Neovascular MembraneUveitisBevacizumab

Outcome Measures

Primary Outcomes (3)

Best corrected visual acuity
Retinal thickness by OCT
Leakage in Fluorescein angiogram

Interventions

BevacizumabDrug

Intravitreal Injection of BevacizumabProcedure

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age25 Years - 60 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Clinical Diagnose
Patient Consent

Sponsors & Collaborators

Asociación para Evitar la Ceguera en México
Otherlead

Study Sites (1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, 04030, Mexico

MeSH Terms

Conditions

Uveomeningoencephalitic SyndromeWhite Dot SyndromesMultifocal ChoroiditisUveitis

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Autoimmune Diseases of the Nervous SystemNervous System DiseasesUveal DiseasesEye DiseasesAutoimmune DiseasesImmune System DiseasesUveitis, PosteriorPanuveitisChoroiditis

Study Officials

Veronica Kon-Jara, MD
Asociación para Evitar la Ceguera en México
PRINCIPAL INVESTIGATOR
LuzElena Concha-Del Rio, MD
Asociación para Evitar la Ceguera en México
STUDY CHAIR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 1, 2006

First Posted

December 4, 2006

Study Start

December 2006

Actual (reported)

NCT00599820

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Phase 3Terminated

NCT00370721

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

Phase 3Unknown

NCT00656435

Bevacizumab and Long Acting Gas in Diabetic Vitrectomy

Phase 3Completed

NCT00370851

Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

Phase 3Completed

NCT00451763

Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia

Phase 3Completed

NCT00370370

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Phase 3Unknown

Chronic stage of inflammation

You may not qualify if:

only eye
age lower than 30 yo.
Systemic condition

Contact the study team to confirm eligibility.

Choroid Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Primary Completion

December 2006

Actual (reported)

Study Completion

December 2006

Actual (reported)

Last Updated

May 30, 2024

Record last verified: 2024-05

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00407121
Data provider: ClinicalTrials.gov
Source updated: 2024-05-30
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:18:30 UTC

Locations

MX(1)

Study Stopped

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations